Optimizing Outcomes for Patients With Curable Bladder Cancer

Video

This video highlights emerging data on genomic markers of response to neoadjuvant chemotherapy for patients with bladder cancer.

In this video, Elizabeth R. Plimack, MD, MS, of Fox Chase Cancer Center in Philadelphia, discusses highlights of a session on bladder cancer from the 2017 Genitourinary Cancers Symposium, held February 16–18 in Orlando, Florida.

Dr. Plimack chaired the session, which focused on optimizing outcomes in muscle-invasive bladder cancer, and gave a presentation on genomic markers of response to neoadjuvant chemotherapy. Emerging data on alterations in DNA repair genes and their association with outcomes are informing clinical trial designs with the aim of studying the feasibility of reducing treatment burden for this patient population.

Recent Videos
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practice in the breast cancer field.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ASCO Annual Meeting, from hot topics and emerging trends to travel recommendations.
Prior studies, like the phase 3 VISION trial, may support the notion of combining radiopharmaceuticals with best supportive care.
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Clinical trials conducted in recent years demonstrate the benefit of integrative oncology for patients undergoing treatment for cancer.
Related Content